គម្របទី ១៩ ៈភាគហ៊ុនកំពូលហ្វាម៉ាម៉ាចំនួន ៥ ដើម្បីវិនិយោគនៅឆ្នាំ ២០២០

អាហ្សេសមូសតាផា

ធ្វើបច្ចុប្បន្នភាព:

ដោះសោសញ្ញា Forex ប្រចាំថ្ងៃ

ជ្រើសរើសគំរោង

£39

1 - ខែ
ការជាវ

ជ្រើសប៊ូតុង

£89

3 - ខែ
ការជាវ

ជ្រើសប៊ូតុង

£129

6 - ខែ
ការជាវ

ជ្រើសប៊ូតុង

£399

ជីវិត
ការជាវ

ជ្រើសប៊ូតុង

£50

ក្រុមជួញដូរ Swing ដាច់ដោយឡែក

ជ្រើសប៊ូតុង

Or

ទទួលបានសញ្ញា Forex VIP សញ្ញាគ្រីបតូ VIP សញ្ញាប្តូរប្រាក់ និងវគ្គសិក្សា Forex ដោយឥតគិតថ្លៃពេញមួយជីវិត។

គ្រាន់តែបើកគណនីជាមួយឈ្មួញកណ្តាលសាខារបស់យើង ហើយធ្វើការដាក់ប្រាក់អប្បបរមា៖ 250 USD ។

អ៊ីមែល [អ៊ីមែលការពារ] ជាមួយរូបថតអេក្រង់នៃមូលនិធិនៅលើគណនីដើម្បីទទួលបានការចូលប្រើ!

ឧបត្ថម្ភដោយ

ការឧបត្ថម្ភ
ការឧបត្ថម្ភ
សញ្ញាធីក

សេវាកម្មសម្រាប់ការជួញដូរចម្លង។ Algo របស់យើងបើក និងបិទការជួញដូរដោយស្វ័យប្រវត្តិ។

សញ្ញាធីក

L2T Algo ផ្តល់សញ្ញាផលចំណេញខ្ពស់ជាមួយនឹងហានិភ័យតិចតួចបំផុត។

សញ្ញាធីក

ការជួញដូររូបិយប័ណ្ណឌីជីថល 24/7 ។ ខណៈពេលដែលអ្នកគេងយើងធ្វើពាណិជ្ជកម្ម។

សញ្ញាធីក

ការរៀបចំ 10 នាទីជាមួយនឹងអត្ថប្រយោជន៍យ៉ាងច្រើន។ សៀវភៅណែនាំត្រូវបានផ្តល់ជូនជាមួយនឹងការទិញ។

សញ្ញាធីក

79% អត្រាជោគជ័យ។ លទ្ធផលរបស់យើងនឹងធ្វើឱ្យអ្នករំភើប។

សញ្ញាធីក

រហូតដល់ 70 ពាណិជ្ជកម្មក្នុងមួយខែ។ មានច្រើនជាង 5 គូ។

សញ្ញាធីក

ការជាវប្រចាំខែចាប់ផ្តើមនៅ£ 58 ។

Even though the highly contagious pandemic Corona (COVID-19) is causing havoc throughout the globe, its consequences were felt in just about all sectors of the world. Biotech firms are in a run-off against-time behind the scenes to create a pathogen vaccine. There are now many investors looking to invest in these firms.

1. GlaxoSmithKline
Being one of the biggest vaccine creators in the world, this British biotech company is at the forefront amongst the firms. It’s known as a pioneer in groundbreaking vaccine production.

The seasonal flu vaccine and the Human Papillomavirus (HPV) vaccine are among the top contributions to the world. It’s collaborating with Clover Biopharmaceuticals, a biotech firm based in China.

Still, they are collaborating on a product for COVID-19 dependent protein vaccine.

2. សាន់ហ្វី
Sanofi Pasteur, a French biotech company, is one of the biggest stakeholders in the battle against Coronavirus under its vaccines division.

It is collaborating with the US Biomedical Advanced Research and Development Authority (BARDA) in collaboration.

BARDA is part of the Health and Human Services Department (HHS), operating under the Office of the Assistant Secretary for Preparation and Response (ASPR).

All consider a preclinical vaccine for SARS as a possible candidate. The candidate for a SARS vaccine was identified in 2017. This could give the company an advantage over competitors because SARS belongs to the class of Coronavirus.

3. ចនសុននិងចនសុន
Janssen, the vaccine subsidiary of Johnson & Johnson, has also been part of the current battle as of January 2020. To win the battle the American pharmaceutical has taken a dual-pronged approach.

On the one side, the antiviral molecules’ library is scanning for a natural fit for the new virus. And on the other hand, it is operating on a vaccine using the same equipment it had previously developed for experimental vaccination against Ebola.

As Sanofi, this also operates in extensive cooperation with BARDA.

4 ។ Gilead Sciences
Better recognized for its medications against the Hepatitis C Virus (HCV), Gilead has been researching on a COVID-19 vaccine. The Remdesivir drug is currently having tests and has positioned the company high on the pharmaceutical companies ‘ crème de la crème list.

This vaccine was originally supposed to cure the Ebola virus and is said to have already aided one Coronavirus patient in the US. More work in China has commenced and the company is expected to begin its very own late-stage tests later in the month.

5. Regeneron Pharmaceuticals
Often, Regeneron works in conjunction with BARDA to create a cure for the virus. This is using a process that has been effective in developing an Ebola virus drug.

This entails introducing genetically engineered mice to the coronavirus proteins with human-like immune systems. The purpose is to have the mice make antibodies to the proteins. Around the same time, people who have stabilized from the illness are using antibodies.

They intend to choose the absolute best from these, which they will use to make a mixture to cure the virus. The product will be ready for human trials by early summer, the company states.

The Stock Market and Coronavirus
This is deserving of notice the pandemic concerns recently caused significant stock market uncertainty. Although rates for some firms have crashed significantly, many have surged. Healthcare and pharmaceutical firms are amongst others.

Considering that these businesses are focused on highly infectious virus therapies, it logically follows that their stocks carry the opportunity for considerable profits. Their commodities also benefit from higher amounts of requests despite the outbreak.

So it’s no mystery that many pharmaceutical stocks, particularly GILD stock, have been on an upswing, surpassing the S&P 500 although it started its steady decline in February.

COVID 19 Vaccine Anticipation
It may take some time, at least one year or more, according to the experts, before the world finally gets a vaccine for the dreaded COVID-19.
Furthermore, introducing those stocks to an investment watchlist is a great way to keep track of their movements as they gain ground in a vaccine’s growth.

A Guide to Invest in Pharma Firms
To U.S. consumers, through Stash Invest, a no-commission stockbroker selling $5 pharmaceutical stocks, you can invest in pharmaceutical companies.

Are you based outside of the USA? We suggest Plus500 which offers low spreads on investments in pharmaceutical stocks and a well-regulated platform.

  • ឈ្មួញកណ្តាល
  • អត្ថប្រយោជន៍
  • ប្រាក់បញ្ញើអប្បបរមា
  • ពិន្ទុ
  • ទស្សនាឈ្មួញកណ្តាល
  • កម្មវិធីជួញដូរគ្រីបតូកូរ៉ូដៀរដែលទទួលបានពានរង្វាន់
  • ការដាក់ប្រាក់អប្បបរមា ១០០ ដុល្លារ,
  • FCA & Cysec មានបទប្បញ្ញត្តិ
$100 ប្រាក់បញ្ញើអប្បបរមា
9.8
  • ប្រាក់បន្ថែមស្វាគមន៍ ២០% រហូតដល់ ១០,០០០ ដុល្លារ
  • ការដាក់ប្រាក់អប្បបរមា ១០០ ដុល្លារ
  • ផ្ទៀងផ្ទាត់គណនីរបស់អ្នកមុនពេលប្រាក់រង្វាន់ត្រូវបានបញ្ចូល
$100 ប្រាក់បញ្ញើអប្បបរមា
9
  • ផលិតផលហិរញ្ញវត្ថុជាង ១០០ ប្រភេទផ្សេងៗគ្នា
  • វិនិយោគចាប់ពី ១០ ដុល្លារឡើងទៅ
  • ការដកប្រាក់នៅថ្ងៃតែមួយគឺអាចធ្វើទៅបាន
$250 ប្រាក់បញ្ញើអប្បបរមា
9.8
  • តម្លៃជួញដូរទាបបំផុត
  • ប្រាក់រង្វាន់ស្វាគមន៍ 50%
  • ការគាំទ្រ ២៤ ម៉ោងឈ្នះរង្វាន់
$50 ប្រាក់បញ្ញើអប្បបរមា
9
  • គណនីមូលនិធិម៉ូនីតាម៉ាឃីតដែលមានអប្បបរមា ៥០០ ដុល្លារ
  • រើសយកដោយប្រើបែបបទដើម្បីទាមទារប្រាក់បន្ថែមពីការដាក់ប្រាក់ ៥០% របស់អ្នក
$250 ប្រាក់បញ្ញើអប្បបរមា
9

ចែករំលែកជាមួយពាណិជ្ជករផ្សេងទៀត!

អាហ្សេសមូសតាផា

Azeez Mustapha គឺជាអ្នកជំនាញផ្នែកពាណិជ្ជកម្មអ្នកវិភាគរូបិយប័ណ្ណអ្នកយុទ្ធសាស្ត្រសញ្ញានិងអ្នកគ្រប់គ្រងមូលនិធិដែលមានបទពិសោធន៍ជាង ១០ ឆ្នាំនៅក្នុងវិស័យហិរញ្ញវត្ថុ។ ក្នុងនាមជាអ្នកសរសេរប្លុកនិងហិរញ្ញវត្ថុគាត់ជួយវិនិយោគិនឱ្យយល់ពីគំនិតហិរញ្ញវត្ថុស្មុគស្មាញបង្កើនជំនាញវិនិយោគរបស់ពួកគេនិងរៀនពីរបៀបគ្រប់គ្រងប្រាក់របស់ពួកគេ។

សូមផ្ដល់យោបល់

អាស័យដ្ឋានអ៊ីមែលរបស់អ្នកនឹងមិនដាក់បង្ហាញជាសាធារណះ។ ត្រូវបំពេញចាំបាច់ពេលមានសញ្ញា * *